Global Oil & Gas Industry Needs to Adopt a Cost Culture

(CHEManager International 3-4/2015)     Abundance of capital investment     With the recent fall-off in oil prices, companies in virtually all sectors of the oil, gas and chemicals (OGC) industry worldwide are going to have to plan and manage their projects for greater capital productivity and along the way create a "cost culture" inside their companies. Prior to the crash in prices "improving throughput" was the single-most important focus for improving capital productivity. That's according to a study conducted by AlixPartners and Oxford Research, which includes a survey of 250 high-level industry executives. Since the late-2000s, higher energy prices and the unconventional-energy boom attracted an abundance of capital investment into the industry globally.

ROCE trends     Compounded ROCE (return on capital employed) averages for all major sectors of the industry were negative for the period 2008-2013 - i.e., even before the recent drops in energy prices. Meanwhile, average returns across all sectors deteriorated, with the E&P sector having some of the most significant declines, from 17% ROCE in 2010 to 6-7% currently (fig. 2). However, within sectors there is a wide dispersion of performance, suggesting that some companies have implemented superior operating models and are able to generate above-average returns, while others struggle. Despite the overall downward trend in capital returns over the past few years there is still an abundance of capital available for companies to invest.

Sustainable returns     According to the study, virtually all executives are frustrated that actual returns are lower than their expectations and that it is taking longer to generate target returns. In North America only 19% of the projects are likely to be delivered on budget, while - depending on the region where projects are managed - 47-61% take longer than expected to generate expected ROI. Only 39% of total respondents said they had a strong series of checks and balances to ensure projects stay on track, and only 11% reported using a stage-gated process to assess project viability. The study concludes that the industry is at an inflection point: to generate sustainable returns, companies need to find a balance of production growth and cost control.



Room for improvement     Overall, when asked to name major challenges to keep projects on budget, the top reason chosen (by 42% of all respondents) was "lack of specialized technology for project execution." 41% of total respondents said they are challenged by "limited synergy with planning and operations" for getting projects completed on time. 30% of all res­pondents stated that "company culture istn't focused on project management." These results show that there is room for improvement in project management, particularly in terms of project execution. The study concludes that in the current environment of falling prices, plus increasing geologic and technical challenges, the creation of an overall cost culture seems to be mandatory.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.